

# SALES & REVENUE REPORT

1 Jan 2021 - 31 Mar 2022

## OVERVIEW






## PRODUCT DETAILS

TOTAL  
CUSTOMERS  
468

TOTAL  
ORDERS  
1.000

TOTAL  
SALES  
146,6 jt

TOTAL  
PROFITS  
84,6 jt





# SALES & REVENUE REPORT

1 Jan 2021 - 31 Mar 2022

OVERVIEW

PRODUCT DETAILS



## Business Insights

1. Peak sales occurred in the 4th quarter, specifically in November 2021
2. The majority of customers are female
3. 50% of total product sales were dominated by Nexium (19.2%), Hydrocodone/APAP (16.2%) and Plavix (14.6%)